Results 11 to 20 of about 92,707 (329)

Phosphodiesterase inhibitors as adjunctive therapies for tuberculosis [PDF]

open access: yesEBioMedicine, 2016
Bintou Ahmadou Ahidjo, William R. Bishai
doaj   +2 more sources

Medication adherence, hospitalization, and healthcare resource utilization and costs in patients with pulmonary arterial hypertension treated with endothelin receptor antagonists or phosphodiesterase type-5 inhibitors

open access: yesPulmonary Circulation, 2020
Adherence to therapy for pulmonary arterial hypertension is essential to optimize patient outcomes, but data on real-world adherence to different pulmonary arterial hypertension drug classes are limited.
Robert P. Frantz   +6 more
doaj   +1 more source

Phosphodiesterase 4 Inhibitors in Allergic Rhinitis/Rhinosinusitis

open access: yesFrontiers in Pharmacology, 2020
Allergic rhinitis/rhinosinusitis (AR) is the most common allergic disease. It affects patients’ quality of life and may influence the severity of lower airway disease such as asthma. Therefore, its treatment is of great importance.
Viera Janosova   +5 more
doaj   +1 more source

Poor outcome of patients with pulmonary arterial hypertension with insufficient response to phosphodiesterase-5 inhibitors alone or in combination with other specific therapy: a registry-based study

open access: yesPulmonary Circulation, 2020
Phosphodiesterase-5 inhibitors are commonly used in pulmonary arterial hypertension but, as suggested by the RESPITE study, phosphodiesterase-5 inhibitor therapy (mono-/combination) does not always have a satisfactory treatment effect.
Clara Hjalmarsson   +8 more
doaj   +1 more source

Selective inhibition of phosphodiesterases 4, 5 and 9 induces HSP20 phosphorylation and attenuates amyloid beta 1-42 mediated cytotoxicity [PDF]

open access: yes, 2016
Phosphodiesterase (PDE) inhibitors are currently under evaluation as agents that may facilitate the improvement of cognitive impairment associated with Alzheimer's disease. Our aim was to determine whether inhibitors of PDEs 4,5 and 9 could alleviate the
Baillie, George S.   +4 more
core   +1 more source

Phosphodiesterase Type 5 Inhibitors, Sport and Doping [PDF]

open access: yes, 2017
Phosphodiesterase type 5 inhibitors (PDE5i) (e.g., sildenafil, tadalafil, vardenafil, and avanafil) are drugs commonly used to treat erectile dysfunction, pulmonary arterial hypertension, and benign prostatic hyperplasia.
Borrione, Paolo   +8 more
core   +1 more source

Nonsteroidal anti-inflammatory drugs as potential ecto-nucleotide phosphodiesterase inhibitors

open access: yesBrazilian Journal of Pharmaceutical Sciences, 2020
Phosphodiesterases (PDE) are group of enzymes which catalyze the hydrolysis of cAMP and cGMP. Since these cyclic phosphate moieties worked as intracellular second messengers in numerous physiological processes, their inhibition can affect normal ...
Shumaila Tasneem   +2 more
doaj   +1 more source

PDE5 inhibitor drugs for use in dementia

open access: yesAlzheimer’s & Dementia: Translational Research & Clinical Interventions, 2023
Alzheimer's disease and related dementias (ADRD) remain a major health‐care challenge with few licensed medications. Repurposing existing drugs may afford prevention and treatment.
Atticus H. Hainsworth   +4 more
doaj   +1 more source

The low KM-phosphodiesterase inhibitor denbufylline enhances neuronal excitability in guinea pig hippocampus in vitro [PDF]

open access: yes, 1990
The actions of the phosphodiesterase inhibitor denbufylline on the excitability of hippocampal neurons were investigated by means of extracellular and intracellular recordings.
Alzheimer, Christian   +3 more
core   +1 more source

Phosphodiesterase Type 5 Inhibitors and Visual Side Effects: A Narrative Review

open access: yesJournal of Ophthalmic & Vision Research, 2021
Phosphodiesterase type 5 inhibitors such as sildenafil citrate and tadalafil are well known for the treatment of erectile dysfunction. However, their use in the presence of pulmonary hypertension can cause ophthalmologic side effects, including non ...
Francisco Barroso   +2 more
doaj   +1 more source

Home - About - Disclaimer - Privacy